Q linea AB
The answer first
Does Q linea beat the market?
No, Q linea has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 21% of Nordic stocks
- Quality82
- Value17
- Trend9
No. 128 of 195 in healthcare
Max for seven days
Follow Q linea with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Q linea
Your first answer is free, no account needed.
Do you own Q linea, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Q linea and a few more. Free, no card.
Super Stock+44.6%In short
- Q linea has fallen 52.2% over the past year, including dividends.
- Overall, Q linea ranks better than 21% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 99.8%. The price is 100.0% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 21% of Nordic stocks.
No. 128 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 47 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.04
- Asset turnoverSales divided by everything the company owns0.04
- Return on equityProfit divided by equity−57.0%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 111 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity0.9
- P/SPrice divided by sales20.8
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 157 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−32.2%
- 6 months−32.0%
- 9 months−50.6%
- 12 months−52.2%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Q linea
2 funds we follow own Q linea. The share is how much of the fund the stock makes up.
- Sweden2
From the funds' latest known holdings.
About Q linea
Q linea AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 66 employees.
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. The company also develops Podler, a portable blood culture technology. It serves physicians, hospitals, laboratories, healthcare payers, and the medical profession.


See the full analysis of Q linea.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card